SUTRO BIOPHARMA, INC. — Form 8-K

Sutro reported Q2 2026 results with $164.3M cash (down from $202.6M in Q1 2026), supporting operations into at least Q2 2028. STRO-004 Phase 1 enrolled 49 patients across dose levels 1–5 mg/kg (completed in 7 months), showing confirmed and ongoing unconfirmed partial responses in pancreatic, head/neck, and lung cancers with favorable tolerability (6% discontinuation rate, mostly grade 1–2 AEs). Dose optimization ongoing between 4–5 mg/kg; maximum tolerated dose not yet defined. STRO-006 (ITGB6-targeting ADC) expected to initiate Phase 1 in Q3 2026; STRO-227 (PTK7-targeting dual-payload ADC) on track for IND submission in 2026. Astellas collaboration yielded $10M milestone in April 2026 for first TROP2-targeting iADC program, now dosing patients in clinic.